Company intelligence / Profile preview

Paddock Laboratories

Minneapolis, Minnesota, United States

Ownership: Private
Employees: ~250
Development stage: Commercial

Overview

Prior to acquisition, marketed ~35 major products with ~20 more in development and about 25 ANDAs pending FDA approval. Focused on niche dosage forms including semi-solids, liquids, powders, tablets, capsules. No clinical trial results reported as it focused on generics.

Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

colistimethate

Commercial

Indications: Bacterial infections

Beyond the preview

Go deeper on Paddock Laboratories.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Paddock Laboratories.

Explore the full profile